
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
Werewolf Therapeutics Inc (HOWL)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: HOWL (1-star) is a SELL. SELL since 5 days. Profits (-17.02%). Updated daily EoD!
1 Year Target Price $7.5
1 Year Target Price $7.5
4 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.98% | Avg. Invested days 21 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 59.23M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 6 | Beta 0.64 | 52 Weeks Range 0.59 - 4.18 | Updated Date 08/15/2025 |
52 Weeks Range 0.59 - 4.18 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.47 | Actual -0.4 |
Profitability
Profit Margin - | Operating Margin (TTM) -6511.2% |
Management Effectiveness
Return on Assets (TTM) -32.66% | Return on Equity (TTM) -82.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4205212 | Price to Sales(TTM) 51.82 |
Enterprise Value 4205212 | Price to Sales(TTM) 51.82 | ||
Enterprise Value to Revenue 3.68 | Enterprise Value to EBITDA 0.57 | Shares Outstanding 44873600 | Shares Floating 26687255 |
Shares Outstanding 44873600 | Shares Floating 26687255 | ||
Percent Insiders 6.07 | Percent Institutions 57.4 |
Upturn AI SWOT
Werewolf Therapeutics Inc
Company Overview
History and Background
Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing transformative cancer therapeutics. Founded in 2017, they leverage their proprietary PREDATORu2122 protein engineering platform to design conditionally activated, non-replicating ADARed cytokine therapeutics.
Core Business Areas
- Drug Development: Focuses on the research, development, and clinical trials of novel ADARed cytokine therapeutics for cancer treatment.
- PREDATORu2122 Platform: This proprietary platform is used to engineer cytokines that are activated specifically in the tumor microenvironment.
- Partnerships and Collaborations: Exploring strategic partnerships and collaborations to expand the development and commercialization of their therapies.
Leadership and Structure
The leadership team consists of experienced executives in drug development and biotechnology. The organizational structure is typical of a clinical-stage biopharmaceutical company.
Top Products and Market Share
Key Offerings
- ATN-103 (iADAREd IL-2): The company's lead clinical candidate is iADAREd IL-2, designed to selectively activate IL-2 in the tumor microenvironment to stimulate anti-tumor immunity. Currently in Phase 1 clinical trials. Competitors developing similar immunotherapies include companies focusing on IL-2 and other cytokine-based treatments.
- ATN-605 (iADAREd IL-15): A pre-clinical candidate, iADAREd IL-15, is another tumor-selective immunotherapy designed to activate IL-15 in the tumor microenvironment. Competitors are developing similar immunotherapies, including those targeting the IL-15 pathway.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the oncology sector, is highly competitive and rapidly evolving. The demand for innovative cancer therapies is strong.
Positioning
Werewolf Therapeutics is positioned as a company developing novel immunotherapies using its proprietary PREDATOR platform to create tumor-selective cytokines. This differentiation aims to improve efficacy and reduce toxicity compared to traditional cytokine therapies.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Werewolf Therapeutics is focused on a sub-segment of this market - cytokine-based immunotherapies - representing a multi-billion dollar opportunity. The company's positioning targets a specific niche in the oncology market, leveraging its proprietary technology.
Upturn SWOT Analysis
Strengths
- Proprietary PREDATOR platform for tumor-selective cytokine development
- Experienced leadership team
- Promising preclinical and early clinical data
- Focus on a high-demand area (oncology immunotherapies)
Weaknesses
- Limited clinical data
- Reliance on a single technology platform
- Cash burn rate typical of clinical-stage biotechs
- Subject to regulatory approval risks
Opportunities
- Positive clinical trial results leading to partnerships and funding
- Expansion of the PREDATOR platform to other targets
- Potential for breakthrough therapy designation or fast track approval
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Economic downturn impacting funding availability
Competitors and Market Share
Key Competitors
- NKTR
- ALKS
- AGEN
- MRTX
Competitive Landscape
Werewolf Therapeutics competes with other companies developing immunotherapies, particularly those focused on cytokines. Its PREDATOR platform offers a potential competitive advantage in terms of tumor selectivity and reduced toxicity.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by progress in clinical development and pipeline expansion.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercialization success. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing ATN-103 through Phase 1 clinical trials and progressing preclinical programs.
Summary
Werewolf Therapeutics is a clinical-stage biotech company focusing on novel cancer immunotherapies. The company's proprietary PREDATOR platform is a key strength, enabling the development of tumor-selective cytokines. Clinical trial outcomes and regulatory approvals are major factors influencing its future success. Competition is intense, and the company faces financial risks typical of early-stage biotechs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Werewolf Therapeutics Inc. website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on publicly available information and is subject to change. Market share data is estimated. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Werewolf Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2021-04-30 | Founder, CEO, President, Secretary & Director Dr. Daniel J. Hicklin Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 46 | Website https://werewolftx.com |
Full time employees 46 | Website https://werewolftx.com |
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.